All In Biotech

Drug Trial Radar · NCT01544595

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 4 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Last checked: Nov 20, 2026Latest source record: Dec 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,147

Actual

Start

Jun 19, 2012

Primary completion

Jun 26, 2017

Study completion Jun 26, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab. Subjects on secukinumab at the end of treatment period in phase III studies (e.g., ongoing CAIN457A2302 and CAIN457A2303 and potentially other secukinumab phase III studies) were eligible to join this extension study. This extension study was planned to collect an additional 2 years of long-term efficacy, safety, and tolerability data of secukinumab in either continuous or interrupted therapy (randomized withdrawal period) in subjects showing at least partial response to secukinumab and completing treatment period on secukinumab in previous phase III studies. In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab were used.

Conditions

  • Moderate to Severe Plaque-type Psoriasis

Interventions

  • Secukinumab (AIN457)Drug

    Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68Time frame: At week 68 (16 weeks after week 52)

Locations

182 sites in 26 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Pasadena, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Snellville, Georgia

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Topeka, Kansas

  • Novartis Investigative Site

    Louisville, Kentucky

  • Novartis Investigative Site

    Louisville, Kentucky

  • Novartis Investigative Site

    Ann Arbor, Michigan

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Rochester, New York

  • Novartis Investigative Site

    High Point, North Carolina

  • Novartis Investigative Site

    Warren, Ohio

  • Novartis Investigative Site

    Oregon City, Oregon

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Duncansville, Pennsylvania

  • Novartis Investigative Site

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Johnston, Rhode Island

  • Novartis Investigative Site

    Charleston, South Carolina

  • Novartis Investigative Site

    Kingsport, Tennessee

  • Novartis Investigative Site

    Nashville, Tennessee

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Salt Lake City, Utah

  • Novartis Investigative Site

    Norfolk, Virginia

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.